Marisa Martín1, Joan Valls2, Angels Betriu3, Elvira Fernández3, Jose M Valdivielso4. 1. Nephrology Service and Unit for the Detection and Treatment of Atherothrombotic Diseases (UDETMA), Hospital Universitari Arnau de Vilanova, IRBLLEIDA. Av. Rovira Roure 80, 25198 Lleida, Spain. Electronic address: mmartinconde@gmail.com. 2. Biostatistics Unit, IRBLLEIDA. Av. Rovira Roure 80, 25198 Lleida, Spain. 3. Nephrology Service and Unit for the Detection and Treatment of Atherothrombotic Diseases (UDETMA), Hospital Universitari Arnau de Vilanova, IRBLLEIDA. Av. Rovira Roure 80, 25198 Lleida, Spain. 4. Experimental Nephrology Laboratory, IRBLLEIDA. Av. Rovira Roure 80, 25198 Lleida, Spain. Electronic address: Valdivielso@medicina.udl.es.
Abstract
BACKGROUND: Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). Serum phosphate has been associated to cardiovascular disease in the general population and this effect seems to be different according to sex. In the present study we analyze the effect of phosphate on subclinical atherosclerosis in the NEFRONA population and its effect depending on sex. DESIGN: Carotid ultrasound assessing the presence of plaques was performed by an itinerant team in 1687 CKD patients not in dialysis without previous cardiovascular events. Standard blood test and anthropometrical parameters were also recorded. RESULTS: Multivariate linear regression to model phosphate levels in patients with CKD showed an interaction of sex with age. Thus, among men, serum phosphate levels declined significantly with age almost linearly. Serum phosphate levels in women under the age of 40-45 years overlapped with those in men and then stayed above, showing and overall constant relationship. Multivariate logistic regression analysis showed that higher phosphate levels associated with a higher risk of presenting atheromatous plaque. This risk however was different according to sex. In men, phosphate levels within the normal range associated with an increased risk of subclinical atheromatosis whereas in women this risk only increased with serum levels over the normal range. CONCLUSIONS: This study demonstrates that phosphate levels are associated with the presence of subclinical atheromatosis in a large CKD population. This effect of phosphate on subclinical atheromatosis was different according to sex, suggesting that a recommended serum phosphate levels could be different for male than for female CKD patients.
BACKGROUND:Cardiovascular disease is the leading cause of mortality in chronic kidney disease (CKD). Serum phosphate has been associated to cardiovascular disease in the general population and this effect seems to be different according to sex. In the present study we analyze the effect of phosphate on subclinical atherosclerosis in the NEFRONA population and its effect depending on sex. DESIGN: Carotid ultrasound assessing the presence of plaques was performed by an itinerant team in 1687 CKDpatients not in dialysis without previous cardiovascular events. Standard blood test and anthropometrical parameters were also recorded. RESULTS: Multivariate linear regression to model phosphate levels in patients with CKD showed an interaction of sex with age. Thus, among men, serum phosphate levels declined significantly with age almost linearly. Serum phosphate levels in women under the age of 40-45 years overlapped with those in men and then stayed above, showing and overall constant relationship. Multivariate logistic regression analysis showed that higher phosphate levels associated with a higher risk of presenting atheromatous plaque. This risk however was different according to sex. In men, phosphate levels within the normal range associated with an increased risk of subclinical atheromatosis whereas in women this risk only increased with serum levels over the normal range. CONCLUSIONS: This study demonstrates that phosphate levels are associated with the presence of subclinical atheromatosis in a large CKD population. This effect of phosphate on subclinical atheromatosis was different according to sex, suggesting that a recommended serum phosphate levels could be different for male than for female CKDpatients.
Authors: Bhupesh Panwar; Suzanne E Judd; Virginia G Wadley; Nancy S Jenny; Virginia J Howard; Monika M Safford; Orlando M Gutiérrez Journal: JAMA Cardiol Date: 2018-04-01 Impact factor: 14.676
Authors: Nicholas C Chesnaye; Yvette Meuleman; Esther N M de Rooij; Ellen K Hoogeveen; Friedo W Dekker; Marie Evans; Agneta A Pagels; Fergus J Caskey; Claudia Torino; Gaetana Porto; Maciej Szymczak; Christiane Drechsler; Christoph Wanner; Kitty J Jager Journal: Clin J Am Soc Nephrol Date: 2022-01-24 Impact factor: 8.237
Authors: Marta Gracia; Àngels Betriu; Montserrat Martínez-Alonso; David Arroyo; María Abajo; Elvira Fernández; José M Valdivielso Journal: Clin J Am Soc Nephrol Date: 2015-12-14 Impact factor: 8.237